Skip to main content
Erschienen in: Current Obesity Reports 2/2023

20.02.2023 | REVIEW

Obesity Paradox: Fact or Fiction?

verfasst von: Stamatia Simati, Alexander Kokkinos, Maria Dalamaga, Georgia Argyrakopoulou

Erschienen in: Current Obesity Reports | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Obesity is related to several comorbidities such as type 2 diabetes mellitus, cardiovascular disease, heart failure, and various types of cancers. While the detrimental effect of obesity in both mortality and morbidity has been well established, the concept of the obesity paradox in specific chronic diseases remains a topic of continuous interest. In the present review, we examine the controversial issues around the obesity paradox in certain conditions such as cardiovascular disease, several types of cancer and chronic obstructive pulmonary disease, and the factors that may confound the relation between obesity and mortality.

Recent Findings

We refer to the obesity paradox when particular chronic diseases exhibit an interesting “paradoxical” protective association between the body mass index (BMI) and clinical outcomes. This association, however, may be driven by multiple factors among which the limitations of the BMI itself; the unintended weight loss precipitated by chronic illness; the various phenotypes of obesity, i.e., sarcopenic obesity or the athlete’s obesity phenotype; and the cardiorespiratory fitness levels of the included patients. Recent evidence highlighted that previous cardioprotective medications, obesity duration, and smoking status seem to play a role in the obesity paradox.

Summary

The obesity paradox has been described in a plethora of chronic diseases. It cannot be emphasized enough that the incomplete information received from a single BMI measurement may interfere with outcomes of studies arguing in favor of the obesity paradox. Thus, the development of carefully designed studies, unhampered by confounding factors, is of great importance.
Literatur
5.
Zurück zum Zitat Weir CB, Jan A. BMI classification percentile and cut off points. 2022 Jun 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Weir CB, Jan A. BMI classification percentile and cut off points. 2022 Jun 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
7.
Zurück zum Zitat WHO. Obesity Fact Sheet (No.311). 2014. WHO. Obesity Fact Sheet (No.311). 2014.
12.
25.
Zurück zum Zitat •• Vecchié A, Dallegri F, Carbone F, Bonaventura A, Liberale L, Portincasa P, et al. Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur J Intern Med. 2018;48:6–17. https://doi.org/10.1016/j.ejim.2017.10.020. Evaluates the association of BMI with mortality and examines obesity phenotypes with different CV risk, aiding to the understanding of the obesity paradox.CrossRefPubMed •• Vecchié A, Dallegri F, Carbone F, Bonaventura A, Liberale L, Portincasa P, et al. Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur J Intern Med. 2018;48:6–17. https://​doi.​org/​10.​1016/​j.​ejim.​2017.​10.​020. Evaluates the association of BMI with mortality and examines obesity phenotypes with different CV risk, aiding to the understanding of the obesity paradox.CrossRefPubMed
36.
Zurück zum Zitat Diletti R, Garcia-Garcia HM, Bourantas C, Van Mieghem NM, van Geuns RJ, Muramatsu T, et al. Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: insights from the international global RESOLUTE program. Catheter Cardiovasc Interv. 2015;85(6):952–8. https://doi.org/10.1002/ccd.25828.CrossRefPubMed Diletti R, Garcia-Garcia HM, Bourantas C, Van Mieghem NM, van Geuns RJ, Muramatsu T, et al. Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: insights from the international global RESOLUTE program. Catheter Cardiovasc Interv. 2015;85(6):952–8. https://​doi.​org/​10.​1002/​ccd.​25828.CrossRefPubMed
38.
Zurück zum Zitat Akin I, Tölg R, Hochadel M, Bergmann MW, Khattab AA, Schneider S, et al. No evidence of “obesity paradox” after treatment with drug-eluting stents in a routine clinical practice: results from the prospective multicenter German DES.DE (German Drug-Eluting Stent) Registry. JACC Cardiovasc Interv. 2012;5(2):162–9. https://doi.org/10.1016/j.jcin.2011.09.021.CrossRefPubMed Akin I, Tölg R, Hochadel M, Bergmann MW, Khattab AA, Schneider S, et al. No evidence of “obesity paradox” after treatment with drug-eluting stents in a routine clinical practice: results from the prospective multicenter German DES.DE (German Drug-Eluting Stent) Registry. JACC Cardiovasc Interv. 2012;5(2):162–9. https://​doi.​org/​10.​1016/​j.​jcin.​2011.​09.​021.CrossRefPubMed
58.
Zurück zum Zitat Zafrir B, Salman N, Crespo-Leiro MG, Anker SD, Coats AJ, Ferrari R, et al. Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016;18(7):859–68. https://doi.org/10.1002/ejhf.551.CrossRefPubMed Zafrir B, Salman N, Crespo-Leiro MG, Anker SD, Coats AJ, Ferrari R, et al. Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016;18(7):859–68. https://​doi.​org/​10.​1002/​ejhf.​551.CrossRefPubMed
69.
Zurück zum Zitat Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, et al. The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial. Eur Heart J. 2016;37(38):2869–78. https://doi.org/10.1093/eurheartj/ehw124.CrossRefPubMed Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, et al. The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial. Eur Heart J. 2016;37(38):2869–78. https://​doi.​org/​10.​1093/​eurheartj/​ehw124.CrossRefPubMed
96.
Zurück zum Zitat National Center for Chronic Disease Promotion and Health Promotion, Office on Smoking and Health. Reports of the Surgeon General. The health consequences of smoking—50 years of progress: a report of the surgeon general. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014. National Center for Chronic Disease Promotion and Health Promotion, Office on Smoking and Health. Reports of the Surgeon General. The health consequences of smoking—50 years of progress: a report of the surgeon general. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014.
Metadaten
Titel
Obesity Paradox: Fact or Fiction?
verfasst von
Stamatia Simati
Alexander Kokkinos
Maria Dalamaga
Georgia Argyrakopoulou
Publikationsdatum
20.02.2023
Verlag
Springer US
Erschienen in
Current Obesity Reports / Ausgabe 2/2023
Elektronische ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-023-00497-1

Weitere Artikel der Ausgabe 2/2023

Current Obesity Reports 2/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.